GPCR250417P30000
- 14.51
- 0.000.00%
Structure Therapeutics Newsroom
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $87
William Blair Maintains Structure Therapeutics(GPCR.US) With Buy Rating
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $60
Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction
Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $118
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $50 to $100
Citizens Capital Markets Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $87
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $80 to $93
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy From Piper Sandler
Structure Therapeutics Analyst Ratings
Buy Rating for Structure Therapeutics: Promising Phase 2b Trials and Strong Financial Position
William Blair Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy From Piper Sandler
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $91
Stifel Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $50
Structure Therapeutics Analyst Ratings
Stifel Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $50
H.C. Wainwright Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $80
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $91